Diabetes impact on nigrostriatal vulnerability in Parkinson's Disease
Galli, A.; Zatti, C.; Lupini, A.; Caminiti, S. P.; Rizzardi, A.; Lucchini, S.; Bertagna, F.; Paghera, B.; Outeiro, T.; Perani, D.; Padovani, A.; Pilotto, A.
Show abstract
Mechanisms underlying the role of diabetes mellitus (DM) as modulator of severity in Parkinsons Disease (PD) remain unclear. Aim of this study was to investigate the impact of DM on nigrostriatal dopaminergic vulnerability considering two independent cohorts of drug-naive PD patients (PPMI and DNA studies). Patients with and without DM were first compared and then matched for age, sex, symptoms severity. Differences in 123I-FP-CIT binding and molecular connectivity alterations were tested in PD with and without DM within the nigrostriatal pathway. 269 drug-naive patients were enrolled (PPMI, n=174; DNA, n=95). In both cohorts, patients with DM were older, predominantly male, and exhibited worse non-motor and cognitive symptoms. After severity-matching, patients with DM were found to exhibit more preserved dopamine binding in striatal regions compared to those without DM, together with a lower neural reserve. Patients with DM showed significant dopaminergic connectivity alterations (20%), primarily due to a loss of connectivity (98%). In contrast, patients without DM had more widespread connectivity changes (33%), characterized by both loss (84%) and gained connections (16%). These findings suggest that diabetes directly affects the nigrostriatal network, resulting in less deficits despite similar disease severity, perhaps decreasing the effect of reserve on dopaminergic neurons loss.
Matching journals
The top 2 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Distinct Longitudinal Clinical-Neuroanatomical Trajectories in Parkinson’s Disease Clinical Subtypes: Insight Towards Precision Medicine 97%
- Nigral pathology contributes to microstructural integrity of striatal and frontal tracts in Parkinson's disease 96%
- Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression 96%
Similar papers in this journal
- Putaminal dopamine modulates movement motivation in Parkinson's disease 96%
- Clinical severity in Parkinson’s disease is determined by decline in cortical compensation 95%
- Parkinson's disease-related Miro1 mutation induces mitochondrial dysfunction and loss of dopaminergic neurons in vitro and in vivo 94%
Similar papers in this journal
Similar papers in this journal
- Apathy progression is associated with brain atrophy and white matter damage in Parkinson's disease 97%
- Disrupted functional brain network associated with presence of hallucinations in Parkinson’s Disease 96%
- White matter microstructure in Parkinson’s disease with and without elevated REM sleep muscle tone 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.